<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693160</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00002457</org_study_id>
    <secondary_id>GM48085</secondary_id>
    <nct_id>NCT00693160</nct_id>
  </id_info>
  <brief_title>Effect of Spinal Ketorolac After Acute Opioid Exposure</brief_title>
  <official_title>Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity Following Acute Opioid Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done because pain is a significant problem for patients with a
      variety of medical problems and following surgery or traumatic injury. Currently available
      pain medications may not treat all types of pain or may treat pain only at doses that produce
      side effects and complications. The medication in this study may have a role in better
      treatment of pain. The goals of this study are to see if a dose of ketorolac (non-narcotic,
      pain reliever), given into the fluid in the back near the spine has any effect on pain or
      discomfort in the skin sensation that will take place after applying capsaicin (chili pepper)
      cream. The sunburn-like sensation that people experience after having capsaicin cream applied
      is similar to, but much milder than, the pain that some people have after surgery and after
      certain types of nerve injuries. This study will test the effects of combining two
      medications that are often given together to control postoperative pain or pain from a nerve
      injury. The investigators are especially interested in answering two questions about the
      effects of ketorolac (non-narcotic pain reliever) and remifentanil (intravenous [IV] narcotic
      painkiller):

        1. How much does remifentanil (narcotic painkiller) affect the sunburn-like painful area on
           your skin, which develops after applying capsaicin cream?

        2. What pain relieving effects does spinal ketorolac have when given with IV remifentanil?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous (IV) remifentanil stimulates spinal COX activity, leading to increased
      Cerebrospinal fluid CSF) prostaglandin E2 (PGE2) concentrations and areas of
      capsaicin-induced mechanical hypersensitivity after remifentanil infusion, and these effects
      will be blocked by intrathecal ketorolac.

      Areas of mechanical hyperalgesia and allodynia will be established by topical capsaicin +
      intermittent heat in healthy volunteers, who will be randomized to receive intrathecal saline
      or ketorolac during remifentanil infusion, with primary outcome measure area of hyperalgesia
      and secondary outcome measure Cerebrospinal fluid (CSF) prostaglandin E2 (PGE2) concentration
      after stopping remifentanil.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the manufacturing of preservative free ketorolac (Acular-PF) was discontinued
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperalgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Total Area of hypersensitivity (measured in centimeters) were assessed approximately 24 hours post intrathecal ketorolac injection by the method of using a von Frey filament</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid (CSF) Prostaglandin E2 (PGE2) Concentration</measure>
    <time_frame>2.5 hours</time_frame>
    <description>Concentration of prostaglandin E2 (PGE2) in Cerebrospinal fluid (CSF) 2.5 hours post injection of intrathecal ketorolac</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Intrathecal Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo intrathecal injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketorolac</intervention_name>
    <description>single intrathecal injection of ketorolac 2 mg</description>
    <arm_group_label>Intrathecal Ketorolac</arm_group_label>
    <other_name>toradol</other_name>
    <other_name>acular pf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subject will receive a placebo (preservative free normal saline) spinal injection</description>
    <arm_group_label>Placebo intrathecal injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>All subjects will receive a remifentanil infusion</description>
    <arm_group_label>Intrathecal Ketorolac</arm_group_label>
    <arm_group_label>Placebo intrathecal injection</arm_group_label>
    <other_name>ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin</intervention_name>
    <description>Topical capsaicin pain model utilized for each subject</description>
    <arm_group_label>Intrathecal Ketorolac</arm_group_label>
    <arm_group_label>Placebo intrathecal injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  American Society of Anesthesiologist (ASA) I or II classification

          -  between the ages of 18-55

          -  weigh less than 250 pounds

          -  without chronic pain

        Exclusion Criteria:

          -  taking analgesics in the last 2 weeks

          -  positive urine drug screen

          -  pregnancy

          -  currently taking any prescription antidepressants or other medications that are mood
             altering

          -  liver or kidney disease

          -  stomach ulcers

          -  allergies to ketorolac, lidocaine, or capsaicin cream

          -  lung disease (COPD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Eisenach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <results_first_submitted>May 15, 2013</results_first_submitted>
  <results_first_submitted_qc>March 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 14, 2014</results_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>analgesia</keyword>
  <keyword>pain</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>31 healthy subjects between the ages of 19-51 were recruited and 30 were randomized between the dates for 11/20/2007 and 8/17/2010. Subjects were seen for all study related visits in the General Clinical Research Center at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intrathecal Ketorolac</title>
          <description>In the presence of a remifentanil infusion subjects received a single intrathecal injection of ketorolac 2 mg.
The remifentanil infusion was initiated in each subject to a target concentration of 1.0 ng/ml using a computer controlled pump and the STANPUMP algorithm. The STANPUMP program, written by Dr. S.L. Shafer of Stanford University permits the administration of a pharmacokinetically tailored infusion to rapidly achieve and maintain a targeted plasma drug concentration.
The remifentanil infusion was titrated based on the subjects’ pain report to a 49 degree Celsius stimulus with the goal of producing approximately 50% decrease in verbal pain report of the 49 degree Celsius stimulus. Upon reaching the target concentration, a steady state infusion was then completed over 80-to 100 minutes.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Intrathecal Injection</title>
          <description>In the presence of remifentanil subjects received a single intrathecal injection of placebo (preservative-free normal saline).
The remifentanil infusion was initiated in each subject to a target concentration of 1.0 ng/ml using a computer controlled pump and the STANPUMP algorithm. The STANPUMP program, written by Dr. S.L. Shafer of Stanford University permits the administration of a pharmacokinetically tailored infusion to rapidly achieve and maintain a targeted plasma drug concentration.
The remifentanil infusion was titrated based on the subjects’ pain report to a 49 degree Celsius stimulus with the goal of producing approximately 50% decrease in verbal pain report of the 49 degree Celsius stimulus. Upon reaching the target concentration, a steady state infusion was then completed over 80-to 100 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intrathecal Ketorolac</title>
          <description>In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo Intrathecal Injection</title>
          <description>In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.78" spread="11.52"/>
                    <measurement group_id="B2" value="32.06" spread="8.52"/>
                    <measurement group_id="B3" value="31.93" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hyperalgesia</title>
        <description>Total Area of hypersensitivity (measured in centimeters) were assessed approximately 24 hours post intrathecal ketorolac injection by the method of using a von Frey filament</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Ketorolac</title>
            <description>In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intrathecal Injection</title>
            <description>In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperalgesia</title>
          <description>Total Area of hypersensitivity (measured in centimeters) were assessed approximately 24 hours post intrathecal ketorolac injection by the method of using a von Frey filament</description>
          <units>centimeters^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" spread="40.5"/>
                    <measurement group_id="O2" value="48.4" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid (CSF) Prostaglandin E2 (PGE2) Concentration</title>
        <description>Concentration of prostaglandin E2 (PGE2) in Cerebrospinal fluid (CSF) 2.5 hours post injection of intrathecal ketorolac</description>
        <time_frame>2.5 hours</time_frame>
        <population>11 Subjects in the Intrathecal Ketorolac group received post study treatment analysis of CSF for PGE2. We were not able to obtain CSF samples in 3 of the subjects post study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Ketorolac</title>
            <description>In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intrathecal Injection</title>
            <description>In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid (CSF) Prostaglandin E2 (PGE2) Concentration</title>
          <description>Concentration of prostaglandin E2 (PGE2) in Cerebrospinal fluid (CSF) 2.5 hours post injection of intrathecal ketorolac</description>
          <population>11 Subjects in the Intrathecal Ketorolac group received post study treatment analysis of CSF for PGE2. We were not able to obtain CSF samples in 3 of the subjects post study drug injection.</population>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="95"/>
                    <measurement group_id="O2" value="75" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Subjects were followed up for 2 weeks and questioned for any adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Intrathecal Ketorolac</title>
          <description>In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo Intrathecal Injection</title>
          <description>In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James C. Eisenach, M.D.</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-4498</phone>
      <email>jimeisenach@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

